| 1.69 0 (0%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.4 | 1-year : | 2.7 |
| Resists | First : | 2.05 | Second : | 2.31 |
| Pivot price | 1.73  |
|||
| Supports | First : | 1.62 | Second : | 1.35 |
| MAs | MA(5) : | 1.68 |
MA(20) : | 1.79 |
| MA(100) : | 2.09 |
MA(250) : | 2.5 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.4 |
D(3) : | 6.3 |
| RSI | RSI(14): 32.4 | |||
| 52-week | High : | 4.59 | Low : | 1.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BMRA ] has closed above bottom band by 25.8%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.63 - 1.64 | 1.64 - 1.66 |
| Close: | 1.67 - 1.69 | 1.69 - 1.71 |
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Thu, 28 May 2026
BMRA Q1 2026 Earnings: Loss of $0.44 Per Share Amid No Revenue Disclosure - Guidance Upgrade Report - Bölüm Sonu Canavarı
Wed, 27 May 2026
BMRA - Biomerica Inc Stock Price and Quote - Finviz
Sat, 23 May 2026
Biomerica Inc. (BMRA) Q1 2026 Earnings: Negative EPS Persists Amid Pre-Revenue Stage - Share Dilution Risk - DonanımHaber
Fri, 22 May 2026
BMRA Q1 2026 Earnings: Biomerica Reports Net Loss of $0.44 Per Share Amid Ongoing Development Efforts - Earnings Beat Streak - dars.gov.et
Thu, 22 May 2025
Biomerica Reports Real-World Data Showing 49% Reduction in IBS S - GuruFocus
Wed, 16 Apr 2025
Biomerica (BMRA) Announces 1-for-8 Reverse Stock Split Effective - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 15.2 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 80 (K) |
| EPS | -1.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.1 |
| Profit Margin | -96.5 % |
| Operating Margin | -131.6 % |
| Return on Assets (ttm) | -54.6 % |
| Return on Equity (ttm) | -94.4 % |
| Qtrly Rev. Growth | -11.9 % |
| Gross Profit (p.s.) | 0.06 |
| Sales Per Share | 1.4 |
| EBITDA (p.s.) | -1.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.05 |
| PEG Ratio | 0 |
| Price to Book value | 1.53 |
| Price to Sales | 1.2 |
| Price to Cash Flow | -1.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|